John F de Groot, Albert H Kim, Sujit Prabhu, Ganesh Rao, Adrian W Laxton, Peter E Fecci, Barbara J O'Brien, Andrew Sloan, Veronica Chiang, Stephen B Tatter, Alireza M Mohammadi, Dimitris G Placantonakis, Roy E Strowd, Clark Chen, Constantinos Hadjipanayis, Mustafa Khasraw, David Sun, David Piccioni, Kaylyn D Sinicrope, Jian L Campian, Sylvia C Kurz, Brian Williams, Kris Smith, Zulma Tovar-Spinoza, Eric C Leuthardt
Background: Treatment options for unresectable new and recurrent glioblastoma remain limited. Laser ablation has demonstrated safety as a surgical approach to treating primary brain tumors. The LAANTERN prospective multicenter registry (NCT02392078) data were analyzed to determine clinical outcomes for patients with new and recurrent IDH wild-type glioblastoma. Methods: Demographics, intraprocedural data, adverse events, KPS, health economics, and survival data were prospectively collected and then analyzed on IDH wild-type newly diagnosed and recurrent glioblastoma patients who were treated with laser ablation at 14 US centers between January 2016 and May 2019...
January 2022: Neuro-oncology advances